Lv0
0 积分 2022-05-17 加入
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study
4天前
已完结
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study
4天前
已完结
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study
5天前
已完结
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study
5天前
已完结
Clinical trial eligibility of a real-world connective tissue disease cohort: Results from the LEAP cohort
5天前
已完结
Selection of study endpoints and patients for clinical trials in primary Sjögren's syndrome
5天前
已完结
Telitacicept: First Approval
11天前
已完结
Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence
11天前
已完结
A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management
11天前
已完结
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
12天前
已完结
皖公网安备34019202002308
